Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy - Top-Institutions - MDSpire

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

  • By

  • Konstantin E. Seifert

  • Hendrik Dinkel

  • Linda Huberth

  • Dorothee Tiedje

  • Jan Gröticke

  • Laura-Maria Krabbe

  • Frederike Tepel

  • Kambiz Rahbar

  • Christof Bernemann

  • Andres J. Schrader

  • Martin Bögemann

  • Martin Janssen

  • Katrin Schlack

  • Barbara Heitplatz

  • January 16, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Urology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Immunotherapy
    • Translational Research

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Urology
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Oncology
    • Immunotherapy

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urology
    • Oncology
    • Clinical Research

Original Source(s)

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

  • by Konstantin E. Seifert, Hendrik Dinkel, Linda Huberth, Dorothee Tiedje, Jan Gröticke, Laura-Maria Krabbe, Frederike Tepel, Kambiz Rahbar, Christof Bernemann, Andres J. Schrader, Martin Bögemann, Martin Janssen, Katrin Schlack, Barbara Heitplatz

  • January 16, 2026

Related Content

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Synthetic short RNA in cancer